【券商聚焦】国金证券:中国双抗/ADC/小核酸具全球竞争力,有望催化创新药新一轮出海与估值重估

金吾财讯
Sep 24

金吾财讯 | 国金证券研究指,2026 WCLC首尔召开,中国创新药密集登场:康方依沃西一线NSCLC头对头优效帕博利珠,PD-1/VEGF双抗领跑IO2.0;翰森/宜联B7-H3ADC进全体会场,ADC向前线+围手术期迁移;KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力,数据国际领先,有望催化创新药新一轮出海与估值重估。风险提示:新药研发失败风险;研发进度低于预期风险;药品降价风险。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10